Details of the Drug Combinations

General Information of This Drug (ID: DM2Y4FG)

Drug Name

PHA-793887 DM2Y4FG

Synonyms

Cyclin-dependent kinase inhibitor (cancer), Nerviano

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

6 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
PHA-793887 + LY335979	DCMI6NI	LY335979	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
PHA-793887 + Mitomycin	DCASNB3	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
PHA-793887 + Idarubicin	DC0WHOZ	Idarubicin	Glioblastoma? (Cell Line: T98G)	[2]
PHA-793887 + PF-562271	DCHNIUG	PF-562271	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
PHA-793887 + Elacridar	DC2MHV0	Elacridar	Human papillomavirus-related cervical adenocarcinoma (Cell Line: KB-ChR-8-5-11)	[2]
PHA-793887 + Ibrutinib	DCCJ2JV	Ibrutinib	Diffuse large B cell lymphoma (Cell Line: TMD8)	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 DrugCom(s)

References

1	A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
2	Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.